World Health Organization member states began voting for the next director-general, with an Ethiopian candidate vying to be the first African to head the United Nations agency.
“As Commissioner, my highest initial priority is to take immediate steps to reduce the scope of the epidemic of opioid addiction. I believe the Food and Drug Administration continues to have an important role to play in addressing this crisis, particularly when it comes to reducing the number of new cases of addiction.” – Scott Gottlieb, M.D., Commissioner of Food and Drugs.
Britain’s competition watchdog has accused Merck & Co. of operating an unfair discount scheme for its medicine Remicade that it said was designed to restrict competition from so-called biosimilar copies.
Bioverativ is buying True North Therapeutics for an upfront payment of $400 million and up to $425 million in milestones.
AstraZeneca’s experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroid drugs in a late-stage study.
FDA Approves Kevzara for Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients
The U.S. FDA approved Sanofi and Regeneron Pharmaceuticals’ Kevzara (sarilumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis.
The U.S. FDA expanded the approved use of subcutaneous Actemra (tocilizumab) to treat adults with giant cell arteritis.
Shares of Puma Biotechnology Inc. surged about 80 percent after the U.S. Food and Drug Administration staffers concluded after a preliminary review that the company’s experimental breast cancer drug was effective.
Celgene Corp. said its oral drug to treat relapsing multiple sclerosis met the main goal in a second late-stage study.
Shares of Amgen fell after the company announced it does not anticipate its experimental osteoporosis drug Evenity will be approved by the U.S. Food and Drug Administration during 2017.